Testosterone cypionate
Depo-Testosterone has defined testosterone-deficiency indications, not an established age-related wellness indication.
FDA-approved product context
Depo-Testosterone has defined testosterone-deficiency indications, not an established age-related wellness indication.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Evidence and source limits
The retrieved Depo-Testosterone label describes intramuscular testosterone cypionate replacement in males with defined primary or hypogonadotropic hypogonadism. It states safety and efficacy for age-related hypogonadism have not been established. DailyMed identifies an ANDA marketing status.
Product labeling and the separate 2025 FDA class-wide update must be read together. Diagnosis, blood-pressure effects, contraindications and monitoring need a licensed clinician. No hormone regimen is provided.
Approval applies to the specific labeled product, route and indication, not every preparation of this ingredient or a wellness mixture. Read the original full label and discuss individual circumstances with a medical professional. No dosing or preparation instructions are included.
Original source: Testosterone cypionate ↗
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.